Study details
Enrolling now
LIFT: Life Improvement Trial
Brigham and Women's Hospital
NCT IDNCT06366724ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
160
Study length
about 2.2 years
Ages
18–70
Locations
1 site in MA
About this study
This trial is testing whether Pyridostigmine, Low-Dose Naltrexone, or a placebo will help people with Long COVID, ME/CFS, or PASC who have Orthostatic Intolerance. It involves 160 participants and will last for about two years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Low-Dose Naltrexone
- 3.Take Pyridostigmine
PhasePhase 2
DrugLow-Dose Naltrexone
Routeinjection
Primary goalPhysiologic Response - Heart Rate Recovery (HRR)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
NERVOUS SYSTEM, pyridostigmine
Drug routes
injection (Injection)
Endpoints
Primary: Physiologic Response - Heart Rate Recovery (HRR)
Secondary: Heart Rate Variability, PROMIS-29-Pain, Resting Heart Rate